Home >> Tag Archives: Horizon Discovery—

Tag Archives: Horizon Discovery—

cfDNA reference standard for EGFR mutations, 3/18

March 2018—Horizon Discovery launched its EGFR Multiplex cfDNA Reference Standard. The cell line-derived EGFR multiplex cell-free DNA reference standard allows laboratories and assay developers to optimize, validate, and routinely monitor performance of polymerase chain reaction–based tests, next-generation sequencing, and other novel assays designed to detect EGFR mutations from cfDNA.

Read More »

Gene and cell therapy platform, 8/17

August 2017—Horizon Discovery announced progress of its gene and cell therapy platform for contract service and therapeutic applications. The offering will make use of Horizon’s suite of gene editing technologies, including CRISPR and its proprietary rAAV and Transposon technologies, to edit pluripotent stem cells and primary human lymphocytes.

Read More »

Horizon, CareDx enter into OEM agreement, 2/17

February 2017—Horizon Discovery Group has entered into an original equipment manufacturer agreement with CareDx. Under the terms of the new agreement, Horizon will supply cell-free DNA-based molecular reference standards for inclusion in CareDx’s cfDNA testing workflows for monitoring transplanted organ rejection.

Read More »

Horizon, Ventana sign co-development agreement, 11/16

November 2016—Horizon Discovery has entered into a co-development and commercialization agreement with Ventana Medical Systems, a member of the Roche group. The agreement covers the development, manufacture, and commercialization of cell-line derivative materials for use as immunohistochemistry reference standards in cancer tissue diagnostics to support the development and validation of IHC assays.

Read More »

Wistar Institute grants Horizon exclusive license , 9/16

September 2016—Horizon Discovery Group and the Wistar Institute announced that Horizon has taken an exclusive license to 153 of Wistar’s melanoma patient-derived xenograft models. Horizon’s distribution of the Wistar melanoma PDX collection will allow scientists worldwide to investigate the efficacy and safety of its drugs prior to trials in human populations.

Read More »

RNA fusion reference standards, 5/16

May 2016—The ALK-RET-ROS1 targeted formalin-fixed, paraffin-embedded RNA Fusion Reference Standards from Horizon are a highly characterized, biologically relevant quality control material to assess the performance of next-generation sequencing, RT-PCR, and RT-qPCR assays aimed at detecting gene fusions.

Read More »